Perrigo OTC Switch Kit Features Rx Generics As Handy Tool
This article was originally published in The Tan Sheet
Executive Summary
Perrigo looks at its Rx topicals and ophthalmic and asthma products "as potential opportunities not just for the generic opportunity, which is good, but for those other opportunities coming into the OTC spot," says CEO Joseph Papa.
You may also be interested in...
Perrigo Closes Q1 Earnings Saga Trying To Keep Grip On Rx Business
The OTC drug private label giant's share price increased as much as 5% in heavy trading May 31 after the release a day earlier of its complete 2017 first-quarter earnings statement and its announcement of $1.4bn in tender offers for credit notes due starting in 2021.
Merck Silence On OTC Singulair Speaks Volumes On Switch Outlook
Merck & Co.’s silence on an OTC version of Singulair is a sign of the relatively “quiet” 2015 switch market despite the call for novel switches, particularly to treat chronic conditions, from FDA’s Nonprescription Drug Safe Use Regulatory Expansion Initiative.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.